Interpretation of Associations in Pharmacoepidemiology

Seminars in Hematology

Volumn 45, Issue 3, 2008, Pages 181-188

  Kaufman, David W ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLDIGOXIN; ANTIHYPERTENSIVE AGENT; ANTITHYROID AGENT; APRINDINE; BETA LACTAM ANTIBIOTIC; BUTAZONE DERIVATIVE; CARBAMAZEPINE; CINEPAZIDE; CLOZAPINE; CORTICOSTEROID; COTRIMOXAZOLE; DIGOXIN; DIPYRIDAMOLE; DIPYRONE; GLIBENCLAMIDE; INDOMETACIN; KETONE DERIVATIVE; MACROLIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROCAINAMIDE; PROPRANOLOL; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; SULFONYLUREA DERIVATIVE; THENALIDINE; TROXERUTIN;

AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTICLE; BLOOD DYSCRASIA; CASE CONTROL STUDY; DATA BASE; DRUG INDUCED DISEASE; HUMAN; PHARMACOEPIDEMIOLOGY; POLYPHARMACY; PRIORITY JOURNAL; RISK FACTOR; SAMPLE SIZE;

CASE-CONTROL STUDIES; DATABASES, FACTUAL; HEMATOLOGY; HUMANS; PHARMACOEPIDEMIOLOGY; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 45749132129     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.04.007     Document Type: Article

References (43)

1. Lubran M.M. Hematologic side effects of drugs. Ann Clin Lab Sci 19 (1989) 114-121
2. Young N.S., and Alter B.P. Aplastic Anemia, Acquired and Inherited (1994), Saunders, Philadelphia, PA
3. Yunis A.A. Chloramphenicol toxicity: 25 years of research. Am J Med 87 (1989) 44N-48N
4. Trevett A.J., and Naraqi S. Saint or sinner?. A look at chloramphenicol. PNG Med J 35 (1992) 210-216
5. Kaufman D.W., Kelly J.P., Jurgelon J.M., Anderson T., Issaragrisil S., Wiholm B.E., et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol 60 suppl (1996) 23-30
6. Ibanez L., Vidal X., Ballarin E., and Laporte J.R. Population-based drug-induced agranulocytosis. Arch Intern Med 165 (2005) 869-874
7. Andersohn F., Konzen C., and Garbe E. Systematic review: Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 146 (2007) 657-665
8. Fung M., Thornton A., Mybeck K., Wu J.H., Hornbuckle K., and Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Inform J 35 (2001) 293-317
9. Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ 172 (2005) 765-767
10. Wysowski D.K., and Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: The importance of reporting suspected reactions. Arch Intern Med 165 (2005) 1363-1369
11. Bennett C.L., Connors J.M., Carwile J.M., Moake J.L., Bell W.R., Tarantolo S.R., et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 342 (2000) 1773-1777
12. Zakarija A., Bandarenko N., Pandey D.K., Auerbach A., Raisch D.W., Kim B., et al. Clopidogrel-associated TTP: An update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 35 (2004) 533-537
13. Strom B.L. What is pharmacoepidemiology?. In: Strom B.L. (Ed). Pharmacoepidemiology. ed 3 (2000), Wiley, Chichester, UK 3-16
14. Rothman K.J., and Greenland S. Modern Epidemiology. ed 2 (1998), Lippincott Williams & Wilkins, Philadelphia, PA
15. Kleinbaum D.G., Kupper L.L., and Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods (1982), Wiley, New York, NY
16. Papanikolaou P.N., Christidi G.D., and Ioannidis J.P. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 174 (2006) 635-641
17. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom B.L. (Ed). Pharmacoepidemiology. ed 4 (2005), Wiley, Chichester, UK 811-829
18. International Agranulocytosis and Aplastic Anaemia Study. Risk of agranulocytosis and aplastic anaemia in relation to use of antithyroid drugs. BMJ 297 (1988) 262-265
19. Kaufman D.W., Kelly J.P., Johannes C.B., Sandler A., Harmon D., Stolley P.D., and Shapiro S. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 82 (1993) 2714-2718
20. Kaufman D.W., Kelly J.P., Levy M., and Shapiro S. The Drug Etiology of Agranulocytosis and Aplastic Anemia: The International Agranulocytosis and Aplastic Anemia Study (1991), Oxford University Press, New York, NY
21. Kaufman D.W., Kelly J.P., Anderson T., Harmon D.C., and Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 38 (1997) 1265-1269
22. List A.F., Vardiman J., Issa J.P., and DeWitte T.M. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program (2004) 297-317
23. Vardiman J.W. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program (2006) 199-204
24. The International Agranulocytosis and Aplastic Anemia Study. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. JAMA 256 (1986) 1749-1757
25. The design of a study of the drug etiology of agranulocytosis and aplastic anemia. A report from the International Agranulocytosis and Aplastic Anemia Study. Eur J Clin Pharmacol 24 (1983) 833-836
26. Leone G., Mele L., Pulsoni A., Equitani F., and Pagano L. The incidence of secondary leukemias. Haematologica 84 (1999) 937-945
27. van Leeuwen F.E., Chorus A.M., van den Belt-Dusebout A.W., Hagenbeek A., Noyon R., van Kerkhoff E.H., et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12 (1994) 1063-1073
28. Csizmadi I., Collett J.-P., and Boivin J.-F. Bias and confounding in pharmacoepidemiology. In: Strom B.L. (Ed). Pharmacoepidemiology. ed 4 (2005), Wiley, Chichester, UK 791-809
29. George J.N., Raskob G.E., Shah S.R., Rizvi M.A., Hamilton S.A., Osborne S., and Vondracek T. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 129 (1998) 886-890
30. Kaufman D.W., Kelly J.P., Rosenberg L., Anderson T.E., and Mitchell A.A. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone S1/2urvey. JAMA 287 (2002) 337-344
31. Patterns of Medication Use in the United States 2006: A Report from the Slone Survey. Slone Epidemiology Center at Boston University, 2007. http://www.bu.edu/slone/SloneSurvey/AnnualRpt/SloneSurveyWebReport2006.pdf (accessed December 4, 2007)
32. Breslow N.E., and Day N.E. Statistical methods in cancer research. Volume I-The analysis of case-control studies. IARC Sci Publ (1980) 5-338
33. Cox D.R., and Oakes D. Analysis of Survival Data (1984), Chapman Hall, London, UK
34. Breslow N.E., and Day N.E. Statistical methods in cancer research. Volume II-The design and analysis of cohort studies. IARC Sci Publ (1987) 1-406
35. Issaragrisil S., Kaufman D.W., Anderson T., Chansung K., Leaverton P.E., Shapiro S., and Young N.S. The epidemiology of aplastic anemia in Thailand. Blood 107 (2006) 1299-1307
36. Baumelou E., Guiguet M., Mary J.Y., and The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Epidemiology of aplastic anemia in France: A case-control study. I. Medical history and medication use. Blood 81 (1993) 1471-1478
37. Handoko K.B., Souverein P.C., van Staa T.P., Meyboom R.H., Leufkens H.G., Egberts T.C., and van den Bemt P.M. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia 47 (2006) 1232-1236
38. Myers M.W., Vasilakis C., Kaufman M.R., and Jick H. Antihypertensive drugs and the risk of idiopathic aplastic anaemia. Br J Clin Pharmacol 49 (2000) 604-608
39. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347 (1996) 1713-1727
40. Shapiro S. Bias in the evaluation of low-magnitude associations: An empirical perspective. Am J Epidemiol 151 (2000) 939-945
41. Honigfeld G., Arellano F., Sethi J., Bianchini A., and Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 59 suppl 3 (1998) 3-7
42. Iqbal M.M., Rahman A., Husain Z., Mahmud S.Z., Ryan W.G., and Feldman J.M. Clozapine: A clinical review of adverse effects and management. Ann Clin Psychiatry 15 (2003) 33-48
43. Clozaril (clozapine). Prescribing Information (May 2005), Novartis Pharmaceuticals, East Hanover, NJ